Table 1.
Patient and treatment characteristics
| Age (years) | |
| Median | 71 |
| IQR | 65–75 |
| Clinical T stage, n (%) | |
| T1c | 24 (9.0) |
| T2a | 24 (9.0) |
| T2b | 14 (5.1) |
| T2c | 18 (6.7) |
| T3a | 135 (50.4) |
| T3b | 48 (17.4) |
| T4 | 5 (1.9) |
| iPSA (ng/mL) | |
| Median | 20.8 |
| IQR | 13.2–36.5 |
| Gleason score, n (%) | |
| 6 | 13 (4.9) |
| 7 | 110 (41.0) |
| 8 | 85 (31.7) |
| 9 | 55 (20.5) |
| 10 | 5 (1.9) |
| NCCN risk classification, n (%) | |
| High-risk | 184 (68.7) |
| Very high-risk | 84 (31.3) |
| NA-ADT, n (%) | |
| CAB | 252 (94.0) |
| LH–RH | 16 (6.0) |
| Duration of NA-ADT (months) | |
| Median | 6.3 |
| IQR | 5.0–7.6 |
| Salvage therapy, n (%) | 87 (32.5) |
| PSA at initiation of salvage therapy (ng/mL) | |
| Median | 5.5 |
| IQR | 4.2–6.6 |
| IMRT | |
| Dose, n (%) | |
| 78 Gy | 208 (77.6) |
| 74 Gy | 60 (22.4) |
IQR interquartile range, iPSA pretreatment prostate-specific antigen, NCCNrisk classification National Comprehensive Cancer Network risk classification ver. 2. 2018; NA-ADT neoadjuvant androgen deprivation therapy, CAB combined androgen blockade, LH–RH luteinizing hormone–releasing hormone analog, IMRT intensity-modulated radiation therapy